Sarcopenia is associated with chemoradiotherapy discontinuation and reduced progression-free survival in glioblastoma patients.
Fabian Martin TroschelBenjamin O TroschelMaren KlossJohanna JostNiklas Benedikt PepperAmelie S TroschelRainer G WiewrodtWalter StummerDorothee WiewrodtHans Theodor EichPublished in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2024)
Sarcopenia is a strong risk factor for treatment discontinuation and reduced progression-free survival in glioblastoma patients. We propose that sarcopenic patients should receive intensified supportive care during radiotherapy and during follow-up as well as expedited access to palliative care.
Keyphrases
- end stage renal disease
- palliative care
- free survival
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- skeletal muscle
- healthcare
- early stage
- squamous cell carcinoma
- radiation therapy
- patient reported outcomes
- locally advanced
- radiation induced
- combination therapy
- community dwelling